HONG KONG SAR -
EQS Newswire - 29 June 2022 - A fully integrated biopharmaceutical
company – Uni-Bio Science Group Limited (the "Company", together with
its subsidiaries, the "Group"; Stock code: 00690.HK) is pleased to
announce that t the marketing application submitted by the Group's
self-developed BOGUTAI® (teriparatide injection) has been accepted by
the China National Medical Products Administration ("NMPA") on 28 June
2022, with the acceptance number "CXSS2200062国". If BOGUTAI® is approved
for marketing, it will provide patients with better drug choices, which
is a major milestone for the company in the field of orthopedic
diseases.
BOGUTAI® (teriparatide injection) is the Group's fifth marketed product
following GENETIME® , GENESOFT® , PINUP® , BOKANGTAI®, and it is also
the first domestic manufactured PTH Liquid in China to use a disposable
injection pen. Developed in collaboration with Swiss self-care giant
Ypsomed, this product has an extremely thin injection needle and high
dose accuracy, which can greatly reduce the pain of injections for
patients. The Group strongly believe BOGUTAI® will be a future
blockbuster for the Group by virtue of the product's strong cost
advantage, better therapeutic effect and convenient administration
method.
Teriparatide injection adopts biological expression technology, and is a
recombinant human parathyroid hormone analog (PTH1-34), which has the
same sequence as the 34-amino acid N-terminal amino acid (biologically
active region) of human parathyroid hormone of 84 amino acids. For the
treatment of osteoporosis in postmenopausal women with a high risk of
fractures, it is the only osteogenesis-promoting anti-osteoporosis drug
approved for marketing at home and abroad, which can effectively improve
bone microstructure, increase bone strength, promote bone healing, and
significantly reduce the risk of vertebral and nonvertebral fractures in
postmenopausal women.
China is the country with the largest number of osteoporosis in the
world. According to the data of the seventh census in 2021, there are
currently 264.02 million people aged 60 and above in my country,
accounting for 18.70%. Epidemiological surveys show that the prevalence
of osteoporosis among people over 50 years old in China is 20.7% for
women and 14.4% for men; the prevalence of osteoporosis among people
over 60 years old is significantly higher, and women are particularly
prominent, as high as 51.6%. Hence, there are currently about 90 million
osteoporosis patients in China, and the osteoporosis market size is
about 15 billion to 20 billion yuan. The current market share of
teriparatide is only about 1% of the PRC osteoporosis market, which is
significantly lower than that of foreign countries. The main reason is
that it is expensive and not covered by medical insurance. However, in
the long run, with the aging of Chinese's population, the gradual
improvement of the coverage of the medical insurance system and the
improvement of residents' purchasing power, the market size of
teriparatide will accelerate significant. Moreover, BOGUTAI's product
positioning of being more cost-effective and safe fits the needs of
target demographic better, ensuring faster growth compared to other
teriparatide competitors.